Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 28 Apr 2025

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases

in Pharmacoepidemiology

Tao Wang
Zhiwei Cui
Yingyong Ou
Siyu Lou
Huayou Chen
Chengyu Zhu
Linmei Zhou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1530697

2,086 views

Original Research

Published on 25 Apr 2025

Acute liver injury and diffuse subcutaneous pneumatosis following compound paracetamol and amantadine hydrochloride tablets poisoning: a case report

in Pharmacoepidemiology

Zhiwen Zhao
Bo Wang
Lanlan Cai
Xuefang Liu
Zhicheng Fang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1503449

1,741 views
1 citation

Systematic Review

Published on 25 Apr 2025

Evaluating the efficacy of valproic acid in alcohol use disorder: a systematic analysis of clinical trials from ClinicalTrials.gov

in Pharmacoepidemiology

Fahad S. Alshehri

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1503035

1,573 views

Original Research

Published on 24 Apr 2025

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database

in Pharmacoepidemiology

Xiang Li
Shu Wen Wang
Zhi-Jie Zhang
Zhan Yang Luo
Jia Feng Tang
Tao Tao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498191

1,792 views

Original Research

Published on 16 Apr 2025

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study

in Pharmacoepidemiology

Yu-Ching Li
Yu-Hsiang Kuan
Yih Yang
Shuo-Yan Gau
Kun-Yu Su
Tung-Han Tsai
Kuang-Hua Huang
Chien-Ying Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1518545

1,319 views

Original Research

Published on 16 Apr 2025

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

in Pharmacoepidemiology

Yunlin Yang
Jinfeng Liu
Wei Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510992

3,406 views

Original Research

Published on 16 Apr 2025

Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology

in Pharmacoepidemiology

Hao Xie
Lin Jiang
Junya Peng
Haoyang Hu
Meifen Han
Bin Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564127

1,862 views

Editorial

Published on 15 Apr 2025

Editorial: Emerging trends in real-world pharmacoepidemiology: 2023

in Pharmacoepidemiology

Mohammed S. Salahudeen
Tatiane Da Silva Dal Pizzol
Li-Ting Kao
Gregory M. Peterson

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601477

1,194 views

Correction

Published on 07 Apr 2025

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Jing Gao
Zhen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586073

748 views

Original Research

Published on 04 Apr 2025

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

in Pharmacoepidemiology

Gashaw Sisay Chanie
Wagaye Atalay
Tirsit Ketsela Zeleke
Zemenu Wube Bayleyegn
Yonas Sisay Aragie
Gizachew Kassahun Bizuneh
Mihret Melese
Rahel Belete Abebe

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1394458

1,232 views

Original Research

Published on 26 Mar 2025

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

in Pharmacoepidemiology

Jiali Xia
Jing Zhang
Hongyu Zhu
Li Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565480

2,244 views

Original Research

Published on 26 Mar 2025

Community pharmacists’ views towards implementing a patient self-administered screening tool designed to identify risk of medication-related problems

in Pharmacoepidemiology

Mohammed S. Salahudeen
Ahmed Samy Saadeldean
Gregory M. Peterson
Behailu Terefe Tesfaye
Colin M. Curtain

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531500

886 views

Original Research

Published on 20 Mar 2025

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

in Pharmacoepidemiology

Feng Zhao
Yulan Chen
Haina Liu
Lei Jin
Xin Feng
Bingbing Dai
Meng Chen
Qiao Wang
Yuxin Yao
Ruobing Liao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1499723

786 views

Systematic Review

Published on 18 Mar 2025

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

in Pharmacoepidemiology

Shuai Geng
Yulong Shen
Chen Zhang
Nan Wang
Xinyue Gao
Xinyu Luo
Ning Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1563566

995 views

Original Research

Published on 12 Mar 2025

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

in Pharmacoepidemiology

Chang-Zhu He
Qin Qiu
Song-Jie Lu
Fu-Li Xue
Jun-Qiao Liu
Yu He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1521358

4,609 views
1 citation

Original Research

Published on 12 Mar 2025

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

in Pharmacoepidemiology

Chengyu Zhu
Zhiwei Cui
Tingting Liu
Siyu Lou
Linmei Zhou
Junyou Chen
Ruizhen Zhao
Li Wang
Yingyong Ou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531514

2,061 views
2 citations